2023
The CARMA Global study, part of the EPIICAL project, has successfully met its recruitment target and recruited 99 children and adolescents living with HIV from across the globe. The study includes children and adolescents who acquired HIV around the period of their birth and then started antiretroviral therapy (ART) at a young age to control the virus and prevent its progression.
The primary aim of CARMA Global is to investigate how the body responds to HIV and how the virus is stored and behaves in the body over time.
2023
Findings from the Strategy for Maintenance of HIV suppression with integrase inhibitor + darunavir/ritonavir in children (PENTA-17) trial, simply known as SMILE, were published in eClinicalMedicine on 2 June 2023. SMILE is the first randomised trial to determine whether children living with HIV on ART with suppressed viral load could maintain the suppression on a once-daily regimen compared to the standard of care (SOC) which involves three ART drugs.
2021
Authors: Cecilia L. Moore, Anna Turkova , Hilda Mujuru , Adeodata Kekitiinwa, Abbas Lugemwa, Cissy M. Kityo, Linda N. Barlow-Mosha, et al, ODYSSEY trial team
Published in: BMC Infectious Diseases
Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy and safety of DTG-based ART compared with standard-of-care in children and adolescents.
2019
Treat early, suppress fast!
In a new paper just published online in Journal of AIDS, EPIICAL researchers investigated the association between the timing of antiretroviral therapy (ART) initiation and time-to suppression among HIV-infected infants who initiated ART within the first 28 days of life.
The study showed as children treated within 7 days of life have a faster time to viral suppression, which may result in a favorable impact on the viral reservoir.